ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

March 9, 2018: By Joan McKenna

ViewPoint Therapeutics announced March 5 that it raised $35 million in a Series B financing.

The biotech company is developing crystallin stabilizers to treat and prevent cataracts and presbyopia using a topical treatment.

ViewPoint said it plans to use the proceeds to advance its lead product candidate, VP1-001, through clinical proof-of-concept studies.

The company says crystallins (alpha-, beta-, and gamma-) are the fibrous proteins that form the majority of the structure of the eye’s natural lens. In their native, properly-folded state, crystallins give the lens its transparency, refractive index, and flexibility.

ViewPoint says it has identified a molecule that effectively stabilizes the soluble native form of alpha-crystallin to reduce misfolding and aggregation, and consequently prevent and counteract lens disorders such as cataracts and presbyopia.

ViewPoint was founded in July 2014 based on technology developed in the lab of Jason Gestwicki at the University of Michigan, in collaboration with the lab of Usha Andley at Washington University in St. Louis. ViewPoint’s operations are based in Janssen Labs in San Francisco.

The financing was led by The Rise Fund with participation from Novo Holdings A/S and other investors. The Rise Fund was co-founded by TPG Growth founder Bill McGlashan, U2 lead singer Bono, and entrepreneur Jeff Skoll.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT